Skip to main content
Advertisement
Advertisement

RKDA

RKDA logo

Arcadia Biosciences, Inc.

0.31
USD
Sponsored
-0.01
-2.66%
Sep 25, 15:58 UTC -4
Closed
exchange

After-Market

0.29

-0.02
-6.70%

RKDA Earnings Reports

Positive Surprise Ratio

RKDA beat 22 of 38 last estimates.

58%

Next Report

Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.45M
/
-$0.46
Implied change from Q2 26 (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
+88.02%
/
-174.19%

Arcadia Biosciences, Inc. earnings per share and revenue

On Aug 12, 2026, RKDA reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.57 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.94 million, with a --% difference.
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.46 USD, with revenue projected to reach 2.45 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
logo
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
logo
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
logo
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
logo
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
logo
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
logo
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
logo
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
FAQ
For Q2 2026, Arcadia Biosciences, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
The next earning report is scheduled for Nov 05, 2026.
Based on 3 analysts, Arcadia Biosciences, Inc. is expected to report EPS of -$0.46 and revenue of $2.45M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement